Johnson & Johnson (NYSE:JNJ) Shares Sold by Acropolis Investment Management LLC

Acropolis Investment Management LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,562 shares of the company’s stock after selling 155 shares during the quarter. Acropolis Investment Management LLC’s holdings in Johnson & Johnson were worth $3,410,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $29,000. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $156.90 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a fifty day moving average price of $153.84 and a 200 day moving average price of $153.70. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a market cap of $377.52 billion, a PE ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Barclays dropped their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Raymond James dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.